From chemotherapy drug J-codes and buy-and-bill to administration coding and regimen-level authorization — SCALE delivers revenue cycle intelligence purpose-built for oncology groups, infusion centers, and MSOs.
Chemo/biologics, buy-and-bill, wastage (JW/JZ)
Hierarchy, hydration & sequencing rules
Regimen-level auth & pathway compliance
White/clear-bagging & payer mandates
Live dashboards via SCALE's analytics platform
Powered by
High-complexity care comes with high-complexity billing — and most generalist RCM vendors aren’t equipped to handle it. SCALE is.
High-cost chemo and biologic buy-and-bill, wastage (JW/JZ), and unit accuracy put six-figure revenue at risk per error.
Initial/sequential/concurrent administration rules and hydration sequencing carry strict documentation requirements.
Payers increasingly require pathway compliance and regimen-level prior authorization that delay treatment and revenue.
Core Service
We manage regimen-level authorization and pathway compliance end to end — including appeals.
AI-Powered
Automated review flags J-code unit, wastage, and administration-hierarchy errors.
Denial Recovery
Payer-specific appeal templates for drug, medical-necessity, and pathway denials.
Specialty Coding
Accurate buy-and-bill, JW/JZ wastage, and administration capture protect high-cost revenue.
Automation handles volume and velocity. Our experts handle exceptions, edge cases, and strategic optimization — creating a closed-loop system that continuously improves performance over time.
We analyze 90 days of claims data to identify coding gaps, denial patterns, and authorization bottlenecks specific to your practice.
Seamless connection to your EHR and practice-management system — no new software for your team to learn or manage.
SCALE’s dedicated team takes over day-to-day RCM operations with transparent reporting from day one.
Monthly performance reviews, payer-policy monitoring, and AI-driven recommendations keep revenue growing over time.
Representative results across SCALE Healthcare clients. Individual outcomes vary by organization size, payer mix, and baseline RCM maturity.
Reduction in average days to pay across SCALE-managed client portfolios
Reduction in cost-to-collect through AI automation and workflow optimization
Reduction in A/R aging beyond 90 days through proactive denial management
Reduction in overall denial rates powered by DenialShield predictive scoring
Book a free 30-minute strategy call with a SCALE Oncology specialist. We’ll review your current denial rates, authorization backlog, and coding performance — at no cost.
